Single Nucleotide SMN1 Variants in a Cohort of Individuals With Spinal Muscular Atrophy
Authors:
- Martina RimoldiMRMartina Rimoldi
- Francesca MagriFMFrancesca Magri
- Megi MeneriMMMegi Meneri
- Valeria Ada SansoneVSValeria Ada Sansone
- Emilio AlbamonteEAEmilio Albamonte
- Linda OttoboniLOLinda Ottoboni
- Giacomo Pietro ComiGCGiacomo Pietro Comi
- Eugenio MercuriEMEugenio Mercuri
- Francesco Danilo TizianoFTFrancesco Danilo Tiziano
- Dario RonchiDRDario Ronchi
- Stefania CortiStefania Corti
Open Access
- 1 October 2025
- journal article
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200286
Abstract
Spinal muscular atrophy 5q (SMA) is a motor neuron disorder caused by recessive pathogenic variants in the SMN1 gene, which encodes the survival motor neuron (SMN) protein. While the majority of patients with SMA exhibit homozygous deletions in SMN1, a minority (2%-5%) of patients with SMA harbor an SMN1 deletion plus a single nucleotide variant on the second allele, which can be identified through direct gene sequencing. The comprehensive characterization of patients with SMA is increasingly crucial considering emerging therapies and newborn screening initiatives. Over the past 20 years, we confirmed a molecular diagnosis of SMA in 149 patients consisting of 138 postnatal and 11 prenatal cases, through a quantitative molecular approach (real-time PCR and/or multiplex ligation-dependent probe amplification) associated with direct sequencing. We identified homozygous SMN1 deletions in 142 probands (95%). The remaining 7 patients (5%) displayed heterozygous SMN1 deletion in compound with a different molecular defect. Notably, 1 patient presented with an intronic variant necessitating mRNA transcript analysis, a process that extended the time to diagnosis. The identification of small pathogenic variants in patients with SMA is of paramount importance for enhancing diagnosis and prognosis, deciphering response variations to existing treatments, and designing novel therapies tailored to address these genetic variants. We propose a paradigm shift from current guidelines, particularly for patients with a heterozygous SMN1 deletion and a clinically compatible SMA phenotype, especially when reduced SMN transcript levels are evident. In such cases, expedited therapy initiation, including reversible treatments like nusinersen or risdiplam, is recommended without waiting for the completion of the molecular testing, thus minimizing delays in crucial therapeutic interventions.Keywords
This publication has 46 references indexed in Scilit:
- The phospho-landscape of the survival of motoneuron protein (SMN) protein: relevance for spinal muscular atrophy (SMA)Cellular and Molecular Life Sciences, 2022
- Impact of missense mutations in survival motor neuron protein (SMN1) leading to Spinal Muscular Atrophy (SMA): A computational approachMetabolic Brain Disease, 2018
- Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular AtrophyJAMA Neurology, 2015
- Newborn and carrier screening for spinal muscular atrophyAmerican Journal of Medical Genetics Part A, 2010
- A rareSMN2variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophyHuman Mutation, 2009
- Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 geneHuman Genetics, 2008
- Nonsense-mediated messenger RNA decay of survival motor neuron 1 causes spinal muscular atrophyHuman Genetics, 2008
- Robust quantification of the SMN gene copy number by real-time TaqMan PCRneurogenetics, 2007
- Molecular analysis of SMA patients without homozygous SMN1 deletions using a new strategy for identification of SMN1 subtle mutationsHuman Mutation, 2004
- An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)Human Mutation, 2000